Project Grant R03CA300831
Award Date
7/15/25
Completion Date
5/31/27
Dollars Obligated
$131K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Tennessee, USA
Similar Awards
This $177,058 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports research to discover and optimize novel anti-mitotic agents for the treatment of metastatic melanoma. The grant aims to develop fused heterocyclic pyrazine (FHP) based tubulin inhibitors that can overcome drug resistance and reduce toxicity associated with current treatments. The research involves three key...
The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), awarded a $607,634 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Mayo Clinic Jacksonville, a nonprofit corporation registered as Scott Lynch MD. The grant, effective January 1, 2025 through December 31, 2029, supports research to develop a first-in-class non-muscle myosin II inhibitor, MT-125, and evaluate its synergistic effects when combined with signal transduction inhibitors and...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $718,113 to St. Jude Children's Research Hospital Inc. to investigate epigenetic modifiers that contribute to the malignancy and plasticity of neuroblastoma, an aggressive pediatric cancer. The goal is to understand how core regulatory circuitry transcription factors (CRC TFs) and MYC oncogenes interact with epigenetic factors like histone deacetylases (HDACs) and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $472,447 to Mayo Clinic to conduct preclinical and clinical research on using DNA methyltransferase (DNMT) inhibitors in combination with standard chemoimmunotherapy for treating triple-negative breast cancer (TNBC). The key objectives are to evaluate the activity and mechanisms of action of DNMT inhibitors in DNMT3A-positive TNBC, clinically assess predictive and pharmacodynamic...
This $377,870 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development and validation of novel synthetic transcriptional repressors (STRs) capable of directly inhibiting the oncogenic transcription factor MYC. The grant aims to: 1) Optimize STR structures for high-affinity and specific binding to MYC target DNA sequences, 2) Enhance cellular and pharmacologic delivery of STRs while mapping their effects on epigenetic and...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $631,492 to The University of Kentucky Research Foundation to identify the metabolic dysregulation and signaling pathways governing metastasis in triple-negative breast cancer (TNBC), and to develop a novel intervention to prevent this deadly disease. The overarching goal is to determine how the enzyme nicotinamide N-methyltransferase (NNMT) promotes TNBC survival and...
The National Cancer Institute awarded a $340,072 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. The grant supports research to evaluate TMU27A, a novel non-nucleoside ribonucleotide reductase (RNR) inhibitor, as a potential treatment for metastatic breast cancer. Proposed studies will investigate TMU27A's impact on genome stability, efficacy, and safety compared to the current RNR...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $542,663 to The University of Texas MD Anderson Cancer Center to conduct preclinical research on using BRG1/BRM antagonists to treat acute myeloid leukemia (AML) with MLL rearrangement or mutant NPM1. The research aims to determine the efficacy of BRG1/BRM inhibitor and degrader compounds, evaluate combination regimens with these agents, and overcome resistance to menin inhibitors...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $768,437 to the Sanford Burnham Prebys Medical Discovery Institute to conduct research aimed at identifying chemical compounds that inhibit the chromatin reader SGF29, which regulates the transcription of oncogenes in acute myeloid leukemia (AML). The research project will implement high-throughput screening assays developed by the institute to screen chemical libraries and identify...
This $530,697 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at the University of Pennsylvania to investigate the use of protein arginine methyltransferase (PRMT) inhibitors for treating high-grade serous ovarian cancer and triple-negative breast cancer. The key objectives are to: 1) characterize the molecular mechanisms of PRMT inhibitor mono- and combination therapies, 2) evaluate the therapeutic potential of PRMT inhibitors in...